Efficacy of Mazdutide in Nondiabetic Adults with Overweight or Obesity: A Meta-Analysis

Purpose Mazdutide is a dual GLP-1 and glucagon receptor agonist under investigation for weight management in obesity. This meta-analysis evaluated its efficacy in nondiabetic adults with overweight or obesity. Methods We searched PubMed, Scopus, and Web of Science for randomized controlled trials (RCTs) comparing mazdutide with placebo. Primary outcomes included changes in body weight, BMI, and waist circumference. A random-effects model was used. Results Four RCTs (n = 918) were included. Mazdutide significantly reduced body weight (MD: − 7.72 kg), BMI (–2.84), waist circumference (–5.76 cm), HbA1c (–0.30%), LDL-C (–10.59 mg/dL), total cholesterol (–18.61 mg/dL), and triglycerides (–49.87 mg/dL). Conclusion Mazdutide demonstrates significant improvements in anthropometric and cardiometabolic outcomes in nondiabetic adults with overweight or obesity, supporting its role as a promising option in overweight and obesity pharmacotherapy.